Allspring Global Investments’s GT Biopharma GTBP Stock Holding History

Allspring Global Investments’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-34	Closed	-$74K	–	2782
2022 Q1	$74K	Buy	+34	New	+$75K	﹤0.01%	2796

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Allspring Global Investments's GTBP Position: Q2 2022 in Review

Allspring Global Investments sold out of GT Biopharma (GTBP) in Q2 2022, closing a stake of 34 shares — an estimated $74K sold.

Allspring Global Investments first reported a position in GTBP in Q1 2022 and held it in 1 quarter. The position peaked at $74K in Q1 2022. 39 funds tracked by Wall St. Rank hold GTBP as of Q2 2022.

Allspring Global Investments reported no remaining GT Biopharma position as of Q2 2022 after selling out during the quarter.
Allspring Global Investments sold 34 GT Biopharma shares in Q2 2022, an estimated $74K.
Allspring Global Investments first reported a position in GT Biopharma in Q1 2022 and held it in 1 quarter.
Allspring Global Investments's GT Biopharma position peaked at $74K in Q1 2022.
39 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.